Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction

Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction Immobilised on a Biodegradable Carrier

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04446897

Enrollment

Registered

2020-06-25

Start date

2020-08-03

Completion date

2020-12-31

Last updated

2021-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis, Chronic

Keywords

Periodontitis, Mesenchymal stem cells

Brief summary

Treatment of chronic medium-severe periodontitis with mesenchymal stem cells and mesenchymal stem cells predifferentiated in osteogenic direction

Detailed description

The bone defect will be filled with a porous membrane based on bone collagen measuring 5x5 mm or more with mesenchymal stem cells and mesenchymal stem cells predifferentiated in osteogenic direction

Interventions

BIOLOGICALmesenchymal stem cells

autologous mesenchymal stem cells

OTHERstandard treatment

standard treatment according to clinical protocols

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

70 Years to 70 Years

Healthy volunteers

Inclusion criteria

\- chronic medium-severe periodontitis

Exclusion criteria

* pregnancy * breast-feeding * acute and chronic infectious diseases: HIV, viral hepatitis, tuberculosis * mental disorders

Design outcomes

Primary

Measure	Time frame	Description
number of patients cured	1 month	number of patients cured

Countries

Belarus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026